'Omic' approaches and lipid metabolism: Are these new technologies holding their promises?

Current Opinion in Lipidology

Volumn 14, Issue 2, 2003, Pages 115-119

  Mooser, Vincent ^a   Ordovas, Jose M ^b  

^a GLAXOSMITHKLINE   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN;

ANALYTIC METHOD; GENOMICS; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TRANSLATION REGULATION;

ANIMALS; CARDIOVASCULAR DISEASES; GENOMICS; HUMANS; LIPID METABOLISM; LIPOPROTEINS;

EID: 0037398060     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200304000-00001     Document Type: Review

References (40)

1. Guttmacher AE, Collins FS. Genomic medicine: a primer. N Engl J Med 2002; 347:1512-1520.
2. McKusick VA, Ruddle FH. Toward a complete map of the human genome. Genomics 1987; 1:103-106.
3. Lee RT. Functional genomics and cardiovascular drug discovery. Circulation 2001; 104:1441-1446.
4. Okazaki Y, Furuno M, Kasukawa T, et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature 2002; 420:563-573.
5. Tefferi A, Bolander ME, Ansell SM, et al. Primer on medical genomics. Part III: microarray experiments and data analysis. Mayo Clin Proc 2002; 77:927-940.
6. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997; 18:533-537.
7. Pardanani A, Wieben ED, Spelsberg TC, Tefferi A. Primer on medical genomics. Part IV: expression proteomics. Mayo Clin Proc 2002; 77:1185-1196.
8. Watkins SM, German JB. Toward the implementation of metabolomic assessments of human health and nutrition. Curr Opin Biotechnol 2002; 13:512-516.
9. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002; 1:153-161.
10. Watkins SM. Comprehensive lipid analysis: a powerful metanomic tool for predictive and diagnostic medicine. Isr Med Assoc J 2000; 2:722-724.
11. Dennis C. Information overload. Nature 2002; 417:14.
12. Baxevanis AD. The molecular biology database collection: 2003 update. Nucleic Acids Res 2003; 31:1-12.
13. van Ommen B, Stierum R. Nutrigenomics: exploiting systems biology in the nutrition and health arena. Curr Opin Biotechnol 2002; 13:517-521.
14. Lawn RM, Wade DP, Garvin MR, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999; 104:R25-R31.
15. Hubacek JA, Berge KE, Cohen JC, Hobbs HH. Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCGS) causing sitosterolemia. Hum Mutat 2001; 18:359-360.
16. Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001; 292:1394-1398.
17. Callow MJ, Rubin EM. Expression profiling and comparative sequence derived insights into lipid metabolism. Curr Opin Lipidol 2002; 13:173-179.
18. Goedert M, Strittmatter WJ, Roses AD. Alzheimer's disease: risky apolipoprotein in brain. Nature 1994; 372:45-46.
19. Ordovas JM, Shen AH. Genetics, the environment, and lipid abnormalities. Curr Cardiol Rep 2002; 4:508-513.
20. Humphries SE, Talmud PJ, Hawe E, et al. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 2001; 358:115-119.
21. Talmud PJ, Humphries SE. Gene: environment interaction in lipid metabolism and effect on coronary heart disease risk. Curr Opin Lipidol 2002; 13:149-154.
22. Smith DJ, Lusis AJ. The allelic structure of common disease. Hum Mol Genet 2002; 11:2455-2461.
23. Corella D, Guillen M, Saiz C, et al. Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the APOE locus. J Lipid Res 2002; 43:416-427.
24. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32:650-654.
25. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-1122.
26. Patil N, Berno AJ, Hinds DA, et al. Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 2001; 294:1719-1723.
27. Roses AD. Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov 2002; 1:541-549.
28. Pennacchio LA, Olivier M, Hubacek JA, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001; 294:169-173.
29. Willson TM, Jones SA, Moore JT, Kliewer SA. Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism. Med Res Rev 2001; 21:513-522.
30. Stulnig TM, Steffensen KR, Gao H, et al. Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. Mol Pharmacol 2002; 62:1299-1305.
31. Hilpert J, Wogensen L, Thykjaer T, et al. Expression profiling confirms the role of endocytic receptor megalin in renal vitamin D3 metabolism. Kidney Int 2002; 62:1672-1681.
32. Debouck C, Metcalf B. The impact of genomics on drug discovery. Annu Rev Pharmacol Toxicol 2000; 40:193-207.
33. Watkins SM, Reifsnyder PR, Pan HJ, et al. Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res 2002; 43:1809-1817.
34. Watkins SM, German JB. Toward the implementation of metabolomic assessments of human health and nutrition. Curr Opin Biotechnol 2002; 13:512-516.
35. Watkins SM, Hammock BD, Newman JW, German JB. Individual metabolism should guide agriculture toward foods for improved health and nutrition. Am J Clin Nutr 2001; 74:283-286.
36. 1H-NMR-based metabonomics. Nat Med 2002; 8:1439-1445.
37. Van Eyk JE. Proteomics: unraveling the complexity of heart disease and striving to change cardiology. Curr Opin Mol Ther 2001; 3:546-553.
38. Macri J, Rapundalo ST. Application of proteomics to the study of cardiovascular biology. Trends Cardiovasc Med 2001; 11:66-75.
39. Arrell DK, Neverova I, Van Eyk JE. Cardiovascular proteomics: evolution and potential. Circ Res 2001; 88:763-773.
40. Bonow R, Clark EB, Curfman GD, et al. Task Force on Strategic Research Direction: Clinical Science Subgroup key science topics report. Circ 2002; 106:e162-e166.